Kaplan–Meier analysis demonstrated increased levels of BRD4 were associated with decreased OS (p = 0.043) in the TCGA cohort (Figure 2E), which is consistent with previous findings that demonstrated that the NSD3–CHD8–BRD4 pathway is amplified in approximately 9% of serous carcinomas, and this amplification leads to a reduced overall survival [20]. Here, BRD4 is linked to serous adenocarcinoma.